Cargando…
The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis
BACKGROUND: This research was conducted to confirm the validity and reliability and to assess the responsiveness and clinical meaningfulness of the OnyCOE-t(™), a questionnaire specifically designed to measure patient-reported outcomes (PRO) associated with toenail onychomycosis. METHODS: 504 patien...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560108/ https://www.ncbi.nlm.nih.gov/pubmed/16911778 http://dx.doi.org/10.1186/1477-7525-4-50 |
_version_ | 1782129465147523072 |
---|---|
author | Potter, Lori P Mathias, Susan D Raut, Monika Kianifard, Farid Tavakkol, Amir |
author_facet | Potter, Lori P Mathias, Susan D Raut, Monika Kianifard, Farid Tavakkol, Amir |
author_sort | Potter, Lori P |
collection | PubMed |
description | BACKGROUND: This research was conducted to confirm the validity and reliability and to assess the responsiveness and clinical meaningfulness of the OnyCOE-t(™), a questionnaire specifically designed to measure patient-reported outcomes (PRO) associated with toenail onychomycosis. METHODS: 504 patients with toenail onychomycosis randomized to receive 12 weeks of terbinafine 250 mg/day with or without target toenail debridement in the IRON-CLAD(® )trial completed the OnyCOE-t™ at baseline, weeks 6, 12, 24, and 48. The OnyCOE-t™ is composed of 6 multi-item scales and 1 single-item scale. These include a 7-item Toenail Symptom assessment, which comprises both Symptom Frequency and Symptom Bothersomeness scales; an 8-item Appearance Problems scale; a 7-item Physical Activities Problems scale; a 1-item Overall Problem scale; a 7-item Stigma scale; and a 3-item Treatment Satisfaction scale. In total, 33 toenail onychomycosis-specific items are included in the OnyCOE-t™. Clinical data, in particular the percent clearing of mycotic involvement in the target toenail, and OnyCOE-t™ responses were used to evaluate the questionnaire's reliability, validity, responsiveness, and the minimally clinical important difference (MCID). RESULTS: The OnyCOE-t™ was shown to be reliable and valid. Construct validity and known groups validity were acceptable. Internal consistency reliability of multi-item scales was demonstrated by Cronbach's alpha > .84. Responsiveness was good, with the Treatment Satisfaction, Symptom Frequency, Overall Problem, and Appearance Problem scales demonstrating the most responsiveness (Guyatt's statistic of 1.72, 1.31, 1.13, and 1.11, respectively). MCID was evaluated for three different clinical measures, and indicated that approximately an 8.5-point change (on a 0 to 100 scale) was clinically meaningful based on a 25% improvement in target nail clearing. CONCLUSION: The OnyCOE-t™ questionnaire is a unique, toenail-specific PRO questionnaire that can be used with confidence in future studies of toenail onychomycosis. MCID was evaluated for three different clinical measures, and indicated that approximately a 7-point change (on a 0 to 100 scale) was clinically meaningful based on a 12.5% improvement in target nail clearing. |
format | Text |
id | pubmed-1560108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15601082006-09-06 The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis Potter, Lori P Mathias, Susan D Raut, Monika Kianifard, Farid Tavakkol, Amir Health Qual Life Outcomes Research BACKGROUND: This research was conducted to confirm the validity and reliability and to assess the responsiveness and clinical meaningfulness of the OnyCOE-t(™), a questionnaire specifically designed to measure patient-reported outcomes (PRO) associated with toenail onychomycosis. METHODS: 504 patients with toenail onychomycosis randomized to receive 12 weeks of terbinafine 250 mg/day with or without target toenail debridement in the IRON-CLAD(® )trial completed the OnyCOE-t™ at baseline, weeks 6, 12, 24, and 48. The OnyCOE-t™ is composed of 6 multi-item scales and 1 single-item scale. These include a 7-item Toenail Symptom assessment, which comprises both Symptom Frequency and Symptom Bothersomeness scales; an 8-item Appearance Problems scale; a 7-item Physical Activities Problems scale; a 1-item Overall Problem scale; a 7-item Stigma scale; and a 3-item Treatment Satisfaction scale. In total, 33 toenail onychomycosis-specific items are included in the OnyCOE-t™. Clinical data, in particular the percent clearing of mycotic involvement in the target toenail, and OnyCOE-t™ responses were used to evaluate the questionnaire's reliability, validity, responsiveness, and the minimally clinical important difference (MCID). RESULTS: The OnyCOE-t™ was shown to be reliable and valid. Construct validity and known groups validity were acceptable. Internal consistency reliability of multi-item scales was demonstrated by Cronbach's alpha > .84. Responsiveness was good, with the Treatment Satisfaction, Symptom Frequency, Overall Problem, and Appearance Problem scales demonstrating the most responsiveness (Guyatt's statistic of 1.72, 1.31, 1.13, and 1.11, respectively). MCID was evaluated for three different clinical measures, and indicated that approximately an 8.5-point change (on a 0 to 100 scale) was clinically meaningful based on a 25% improvement in target nail clearing. CONCLUSION: The OnyCOE-t™ questionnaire is a unique, toenail-specific PRO questionnaire that can be used with confidence in future studies of toenail onychomycosis. MCID was evaluated for three different clinical measures, and indicated that approximately a 7-point change (on a 0 to 100 scale) was clinically meaningful based on a 12.5% improvement in target nail clearing. BioMed Central 2006-08-15 /pmc/articles/PMC1560108/ /pubmed/16911778 http://dx.doi.org/10.1186/1477-7525-4-50 Text en Copyright © 2006 Potter et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Potter, Lori P Mathias, Susan D Raut, Monika Kianifard, Farid Tavakkol, Amir The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title | The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title_full | The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title_fullStr | The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title_full_unstemmed | The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title_short | The OnyCOE-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
title_sort | onycoe-t™ questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560108/ https://www.ncbi.nlm.nih.gov/pubmed/16911778 http://dx.doi.org/10.1186/1477-7525-4-50 |
work_keys_str_mv | AT potterlorip theonycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT mathiassusand theonycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT rautmonika theonycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT kianifardfarid theonycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT tavakkolamir theonycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT potterlorip onycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT mathiassusand onycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT rautmonika onycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT kianifardfarid onycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis AT tavakkolamir onycoetquestionnaireresponsivenessandclinicalmeaningfulnessofapatientreportedoutcomesquestionnairefortoenailonychomycosis |